Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Buy
62
IMDX Quote, Financials, Valuation and Earnings
Last price:
$6.51
Seasonality move
:
9.95%
Day range:
$6.04 - $6.74
52-week range:
$1.95 - $8.51
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
39.67x
P/B ratio:
196.14x
Volume:
39.9K
Avg. volume:
38K
1-year change:
224.38%
Market cap:
$186.9M
Revenue:
$1.9M
EPS (TTM):
-$2.83
Analysts' Opinion
-
Consensus RatingInsight Molecular Diagnostics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.00, Insight Molecular Diagnostics, Inc. has an estimated upside of 7.36% from its current price of $6.52.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $6.52.
Fair Value
-
According to the consensus of 3 analysts, Insight Molecular Diagnostics, Inc. has 7.36% upside to fair value with a price target of $7.00 per share.
IMDX vs. S&P 500
-
Over the past 5 trading days, Insight Molecular Diagnostics, Inc. has underperformed the S&P 500 by -1.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Insight Molecular Diagnostics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Insight Molecular Diagnostics, Inc. has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Insight Molecular Diagnostics, Inc. reported revenues of $260K.
Earnings Growth
-
Insight Molecular Diagnostics, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Insight Molecular Diagnostics, Inc. reported earnings per share of -$0.34.
Enterprise value:
170.6M
EV / Invested capital:
--
Price / LTM sales:
39.67x
EV / EBIT:
--
EV / Revenue:
38.75x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-7.13x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$291.5K
Return On Assets:
-116.83%
Net Income Margin (TTM):
-1380.69%
Return On Equity:
-1008.03%
Return On Invested Capital:
-1767.73%
Operating Margin:
-2950%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.3M | $709K | $4.4M | $115K | $260K | |
| Gross Profit | -$2.1M | -$950.5K | $291.5K | -$268K | -$423K | |
| Operating Income | -$25.1M | -$22.9M | -$26.1M | -$6.4M | -$7.7M | |
| EBITDA | -$22.3M | -$21.6M | -$23.9M | -$6M | -$7.1M | |
| Diluted EPS | -$23.40 | -$4.41 | -$2.83 | -$0.98 | -$0.34 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $47.6M | $36.6M | $16.9M | $4.5M | $21.4M | |
| Total Assets | $168.3M | $157.3M | $81.6M | $70.2M | $43.9M | |
| Current Liabilities | $13.4M | $13M | $8M | $9.1M | $7.7M | |
| Total Liabilities | $69M | $75.4M | $39.1M | $60.5M | $53.1M | |
| Total Equity | $99.3M | $81.9M | $42.5M | $9.7M | -$9.2M | |
| Total Debt | $5.5M | $3M | $2.4M | $3.1M | $2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$19.9M | -$22M | -$5.6M | -$4.5M | |
| Cash From Investing | -- | -$61K | -$1.9M | -$87K | -$1.1M | |
| Cash From Financing | -- | $9.6M | $39.2M | -$255K | -$120K | |
| Free Cash Flow | -- | -$20.5M | -$23.9M | -$5.6M | -$5.6M | |
IMDX
Sector
Market Cap
$186.9M
$25.9M
Price % of 52-Week High
76.62%
51.6%
Dividend Yield
0%
0%
Shareholder Yield
-41.78%
-1.66%
1-Year Price Total Return
224.38%
-18.99%
Beta (5-Year)
1.109
0.485
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$6.65
200-day SMA
Buy
Level
$4.06
Bollinger Bands (100)
Buy
Level
3.61 - 6.83
Chaikin Money Flow
Buy
Level
14.8K
20-day SMA
Sell
Level
$6.82
Relative Strength Index (RSI14)
Sell
Level
49.63
ADX Line
Sell
Level
7.14
Williams %R
Neutral
Level
-67.3469
50-day SMA
Buy
Level
$6.30
MACD (12, 26)
Buy
Level
0.52
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Sell
Level
-39.9K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-15.4522)
Sell
CA Score
(Annual)
Level (-4.0979)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (11.6184)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Insight Molecular Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Nashville, TN.
Stock Forecast FAQ
In the current month, IMDX has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The IMDX average analyst price target in the past 3 months is $7.00.
-
Where Will Insight Molecular Diagnostics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Insight Molecular Diagnostics, Inc. share price will rise to $7.00 per share over the next 12 months.
-
What Do Analysts Say About Insight Molecular Diagnostics, Inc.?
Analysts are divided on their view about Insight Molecular Diagnostics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Insight Molecular Diagnostics, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Insight Molecular Diagnostics, Inc.'s Price Target?
The price target for Insight Molecular Diagnostics, Inc. over the next 1-year time period is forecast to be $7.00 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is IMDX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Insight Molecular Diagnostics, Inc. is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of IMDX?
You can purchase shares of Insight Molecular Diagnostics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Insight Molecular Diagnostics, Inc. shares.
-
What Is The Insight Molecular Diagnostics, Inc. Share Price Today?
Insight Molecular Diagnostics, Inc. was last trading at $6.51 per share. This represents the most recent stock quote for Insight Molecular Diagnostics, Inc.. Yesterday, Insight Molecular Diagnostics, Inc. closed at $6.52 per share.
-
How To Buy Insight Molecular Diagnostics, Inc. Stock Online?
In order to purchase Insight Molecular Diagnostics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get IMDX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IMDX
Sector
P/E ratio
--
23.82x
PEG ratio
--
-0.01x
P/B ratio
196.14x
1.83x
Price / LTM sales
39.67x
1.56x
Growth Metrics
IMDX
Sector
Revenue growth
126.09%
4.18%
Earnings growth
65.57%
9.66%
Revenue (5-year growth)
--
6.28%
Earnings forecast
-$0.23
-$0.18
Profitability
IMDX
Sector
Profitability FY 2024
-$666K
$3.1M
Return on invested capital
-1767.73%
-32.89%
Return on assets
-116.83%
-29.56%
Return on equity
-1008.03%
-38.66%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
24
Estimated Next Earnings Date
Feb
9
Balance Sheet
IMDX
Sector
Total cash
$19.4M
$25.2M
Short term investments
--
$25.1M
Total assets
$35.1M
$73M
Long term debt
$2M
$3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
47
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
56
INTC alert for Jan 24
Intel Corp. [INTC] is down 17.01% over the past day.
Buy
64
BNR alert for Jan 24
Burning Rock Biotech Ltd. [BNR] is down 12.81% over the past day.
Sell
19
APGE alert for Jan 24
Apogee Therapeutics, Inc. [APGE] is down 12.28% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
